Advertisement

ChromaDex Corporation CDXC

Set alert

Price alert · CDXC

All alert types
7.87 0.00 0.00%

At close · Mar 18

7.75 Day range 7.92

52-week range unavailable

YTD
+48.21%
1 year
+163.21%
Open
7.91
Prev close
7.87
Mkt cap
404.83M
Vol
541.67K
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
7.75
High
7.92
Forward P/E
44.17
Beta
1.88
Short ratio
0.72
Inst. own
23.92%
Dividend
0.00
Ex-div date
50-d avg
5.81
200-d avg
3.86
1y target
7.96

3M chart

Chart tools
Interval

Signals (21)
NameDateAgo
SMA: BearishApr 4, 20251 year ago
SMA: BearishApr 3, 20251 year ago
SMA: BullishApr 2, 20251 year ago
SMA: BearishMar 28, 20251 year ago
MACD: Sell SignalMar 24, 20251 year ago
SMA: BullishMar 5, 20251 year ago
SMA: BullishMar 5, 20251 year ago
MACD: Buy SignalMar 5, 20251 year ago
RSI: OverboughtMar 5, 20251 year ago
SMA: BearishMar 3, 20251 year ago
SMA: BullishFeb 28, 20251 year ago
MACD: Sell SignalFeb 24, 20251 year ago
SMA: BearishFeb 21, 20251 year ago
SMA: BearishFeb 20, 20251 year ago
SMA: BullishFeb 14, 20251 year ago
SMA: BullishFeb 14, 20251 year ago
MACD: Buy SignalFeb 14, 20251 year ago
SMA: BearishFeb 7, 20251 year ago
SMA: BullishFeb 5, 20251 year ago
MACD: Sell SignalFeb 4, 20251 year ago
SMA: BullishJan 17, 20251 year ago

Key statistics

Market cap
404.83M
Enterprise value
390.91M
Trailing P/E
265.00
Forward P/E
44.17
PEG ratio
0.00
Price / sales
4.42
Price / book
11.75
EPS (TTM)
0.02
Beta
1.88
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
1.62%
Revenue (TTM)
91.67M
Revenue growth
31.20%
Free cash flow
4.38M
Total cash
32.25M
Total debt
2.90M
Return on equity
4.81%
Shares outstanding
76.38M
Short % of float
4.04%
50-day average
5.81
200-day average
3.86

Analyst view

Consensus: none

Price target (mean) 7.96 +1.1% upside
Target (low)
5.00
Target (mean)
7.96
Target (high)
12.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy3
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate 0.018.

Earnings history

Financials — quick view

All financials
CDXC Revenue — quarterly 29.13M
2021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 2024
CDXC Net income — quarterly 7.18M
2021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 2024
CDXC EPS — quarterly 0.09
2021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 2024

Earnings

CDXC recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Oct 31, 2024Sep 1, 20240.010.02+0.01+100.00%
Aug 7, 2024Jun 1, 2024-0.030.00——
May 8, 2024Mar 1, 2024-0.03-0.01+0.02+66.67%
Mar 6, 2024Dec 1, 2023-0.030.00——
Nov 8, 2023Sep 1, 2023-0.03-0.01+0.02+66.67%
Aug 9, 2023Jun 1, 2023-0.04-0.03+0.01+25.00%

Upgrades / downgrades

CDXC analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2024Roth MKMmainBuyBuy
Nov 4, 2024HC Wainwright & Co.mainBuyBuy
Aug 9, 2024HC Wainwright & Co.reitBuyBuy
Jul 15, 2024HC Wainwright & Co.reitBuyBuy
Jun 12, 2024Roth MKMmainBuyBuy
May 9, 2024HC Wainwright & Co.reitBuyBuy

About ChromaDex Corporation

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Sector
Consumer Defensive
Industry
Packaged Foods
Country
United States

News

Your note

Sign in to keep a note on CDXC — it syncs with the Stock Master app.

Insider holders

CDXC insider holders
InsiderRelationLatest transactionDateShares held
CHAMPION RIVER VENTURES, LTD.Director and Beneficial Owner of more than 10% of a Class of SecurityPurchaseSep 5, 20230
CHAU HOI SHUEN SOLINA HOLLYBeneficial Owner of more than 10% of a Class of SecurityPurchaseAug 19, 20240
FRIED ROBERT NChief Executive OfficerPurchaseMay 30, 20230
GERBER BRIANNAChief Financial OfficerPurchaseNov 30, 202328,674
JAKSCH FRANK LOUIS JRDirectorSaleDec 12, 20242,319,230
LI KA SHINGBeneficial Owner of more than 10% of a Class of SecuritySaleAug 19, 20240

Institution ownership

CDXC institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc4.49%3,430,35618.18MSep 29, 2024
Blackrock Inc.4.45%3,395,35818.00MSep 29, 2024
Tieton Capital Management, LLC3.87%2,956,12015.67MSep 29, 2024
ICONIQ Capital, LLC1.70%1,296,3546.87MSep 29, 2024
Geode Capital Management, LLC1.51%1,149,5926.09MSep 29, 2024
State Street Corporation0.81%618,0283.28MSep 29, 2024

Fund ownership

CDXC fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.88%2,196,48411.64MSep 29, 2024
iShares Russell 2000 ETF1.58%1,210,4046.42MOct 30, 2024
Vanguard Extended Market Index Fund1.02%776,0704.11MSep 29, 2024
Fidelity Small Cap Index Fund0.66%501,7042.66MAug 30, 2024
iShares Russell 2000 Growth ETF0.55%421,3922.23MOct 30, 2024
Fidelity Extended Market Index Fund0.39%299,1901.59MOct 30, 2024
Advertisement